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Background: Hospital antimicrobial stewardship (AMS) programmes are multidisciplinary initiatives to optimize
antimicrobial use. Most hospitals depend on time-consuming manual audits to monitor clinicians’ prescribing.
But much of the information needed could be sourced from electronic health records (EHRs).
Objectives: To develop an informatics methodology to analyse characteristics of hospital AMS practice using
routine electronic prescribing and laboratory records.
Methods: Feasibility study using electronic prescribing, laboratory and clinical coding records from adult patients
admitted to six specialities at Queen Elizabeth Hospital, Birmingham, UK (September 2017–August 2018).
The study involved: (i) a review of AMS standards of care; (ii) their translation into concepts measurable from
commonly available EHRs; and (iii) a pilot application in an EHR cohort study (n"61679 admissions).
Results: We developed data modelling methods to characterize antimicrobial use (antimicrobial therapy
episode linkage methods, therapy table, therapy changes). Prescriptions were linked into antimicrobial therapy
episodes (mean 2.4 prescriptions/episode; mean length of therapy 5.8 days), enabling several actionable find-
ings. For example, 22% of therapy episodes for low-severity community-acquired pneumonia were congruent
with prescribing guidelines, with a tendency to use broader-spectrum antibiotics. Analysis of therapy changes
revealed IV to oral therapy switching was delayed by an average 3.6 days (95% CI: 3.4–3.7). Microbial cultures
were performed prior to treatment initiation in just 22% of antibacterial prescriptions. The proposed methods
enabled fine-grained monitoring of AMS practice down to specialities, wards and individual clinical teams by
case mix, enabling more meaningful peer comparison.
Conclusions: It is feasible to use hospital EHRs to construct rapid, meaningful measures of prescribing quality
with potential to support quality improvement interventions (audit/feedback to prescribers), engagement with
front-line clinicians on optimizing prescribing, and AMS impact evaluation studies.
Introduction
The aims of antimicrobial stewardship (AMS) are ‘first, to ensure ef-
fective treatment of patients with infection, and second, to minim-
ize collateral damage from antimicrobial use’.1 Hospital AMS
guidelines2–7 recommend regular clinical audits of prescriptions
and feedback of results to prescribers by infection specialists. Yet,
doing so is labour-intensive and dependent on specialist expert-
ise,8 as it involves reviewing what diagnostic tests were performed
and assessing the compliance with local prescribing guidelines.
Similarly, point prevalence surveys conducted for infection surveil-
lance9 can be prohibitive both in terms of professional time and
methodological skill. This hinders hospitals’ capacity to monitor
prescribing on a large scale.8,10,11
Electronic health records (EHRs) collected routinely by hospital
information systems offer potential solutions to this problem. King
et al.12 and Hand et al.13 scoped the potential role of electronic pre-
scribing software in supporting prescribers across the full antibiotic
lifecycle (prescription initiation, review, discontinuation and
dispensing of discharge medications). Other studies have demon-
strated the feasibility of using computerized laboratory results,
including microbial cultures and sensitivities, to guide the choice
of antimicrobial agent in empirical therapy14 and increase the
proportion of cases treated with effective antimicrobials.15
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EHRs thus have the potential to enable a range of functions rec-
ommended in AMS guidelines,2 particularly: audit of practice, feed-
back to prescribers, and infection surveillance (tracking syndromes,
pathogens and susceptibility). Despite this, the use of EHRs to
drive AMS programmes remains ‘underexploited’.16 Extraction of
records is challenging,17 resulting in very limited secondary use for
evidence-based medicine.18 In response, the UK’s Antimicrobial
Resistance National Action Plan set goals for a comprehensive use
of EHRs to ‘support and drive good antimicrobial stewardship by
coding, auditing and providing feedback for surveillance’ by 2025.16
The aim of the present paper was to assess the feasibility of
auditing antimicrobial stewardship practices using routinely col-
lected EHRs in order to provide relevant information to different AMS
stakeholders including clinicians, hospital managers and policy-
makers. Key objectives were to: (i) infer the indication of antibiotics
prescribed to inpatients; (ii) assess the congruence of individual pre-
scriptions with local prescribing guidelines, particularly in relation to
empirical therapy; (iii) compute metrics of stewardship beyond con-
sumption of antibiotics; and (iv) compare these metrics between
specialities and between consultant teams within specialities.
This feasibility study followed three steps. First, we synthesized
concepts relevant to antimicrobial stewardship performance from
clinical guidelines and infection surveillance protocols and trans-
lated them into operational definitions applicable to EHRs. Second,
we modelled and visualized records to refine definitions that could
be applied to data from one specialist hospital in Birmingham, UK.
Third, we computed AMS metrics and reviewed compliance of
clinical practices with AMS guidelines.
Materials and methods
Ethics
This research was approved by University College London’s Research Ethics
Committee (REC reference 16765/002). Informed consent was not sought
for the secondary analysis of pseudonymized EHRs.
Study design and population
We conducted a retrospective cohort study of records corresponding to epi-
sodes of care in six specialities (general medicine, respiratory medicine,
geriatric medicine, cardiology, general surgery, urology) at Queen Elizabeth
Hospital Birmingham (QEHB) for adult inpatients admitted between 1
September 2017 and 31 August 2018 (n"61679 admissions). QEHB is a
specialist teaching hospital in Birmingham, UK with over 1000 general and
acute inpatient beds.
Variables
Pseudonymized EHRs consisted of patient demographics, clinical diagnosis
codes (ICD-10,19 reclassified as shown in Table S3, available as
Supplementary data at JAC-AMR Online), clinical procedure codes (OPCS-
4),20 episodes of care (pseudonymized consultant code, consultant special-
ity), ward movements, and key investigation results (blood counts, vital
signs, blood pressure, organ function).
Antibacterial drug prescription and administration records were
extracted from QEHB’s locally developed Prescribing, Information and
Communication System (PICS).21 PICS follows the common UK ‘dose-
based’ prescribing approach,22 in which prescribers issue a request contain-
ing one or more drug names (Trade Family), dose, route and frequency.
Microbial culture results, including no-growth results and cultures
ordered by general practitioners were extracted from PICS. We applied
EUCAST interpretative criteria,23 and classified bacterial isolates by MDR
profile (multiple, extensive and pan-drug resistance) according to rules set
out by Magiorakos et al.24 CURB-65,25 an important risk stratification score
for community-acquired pneumonia (CAP), was computed without the
confusion score due to lack of reliable data.
AMS metrics
Relevant definitions and standards of care were identified from internation-
al hospital antimicrobial stewardship and infection treatment guidelines
using a list systematically compiled in 2018,26 alongside four UK-specific
reference sources.2,9,27,28 We narrowed down a list of measures (Table 1)
on the basis of (i) their relevance to inform a hospital AMS strategy and (ii)
the availability of sufficient information to measure them within commonly
encountered EHRs. These measures characterize the following:
• Antimicrobial consumption (dose and duration). Defined daily doses,
days of therapy (DOT), and length of therapy (LOT: duration of the epi-
sode, irrespective of the number of antimicrobials administered concur-
rently) were calculated and aggregated by ward, speciality, consultant
teams, and clinical indication as per definitions by Ibrahim et al.29
• Changes of therapy tracked changes in antibacterial treatment choices
across a ‘therapy episode’ (Data modelling section) and their timing
relative to microbiological outcomes and clinical progression. One such
change, de-escalation, is recommended when microbial culture and
susceptibilities are available, or when there is limited evidence of infec-
tion. It is most easily measured in antibiotics with the broadest spec-
trum of activity, where only a small number of other drugs would have
equivalent spectrum. Conversion from IV therapy to oral therapy is an-
other commonly recommended change of therapy intervention, which
can facilitate discharge and reduce some adverse effects of injec-
tions.30 We computed the time by which criteria for switching from IV
to oral regimens were met, based on a set of ‘ABCD’ criteria listed in
QEHB’s antimicrobial prescribing guidelines (Table 2), some of which are
in common with the Glasgow Audit Tool.28 Out of these, ability to take
oral medication (criterion B) could not be assessed from records, but
other criteria could be measured continuously.
• Congruence of practice with prescribing guidelines. Prescriptions
starting a therapy episode were compared with first-line choice of
empirical therapy recommended in local prescribing guidelines.
• Adherence to microbial sampling guidelines recommending
submission of bacterial cultures prior to initiation of empirical treat-
ment.27 We computed the proportion of prescriptions with a micro-
bial sample taken in the 3 days leading up to antibacterial therapy
initiation.
Underlying concepts are defined and mapped to relevant SNOMED CT
concept codes31 in Table S1.
Data modelling
Graph theory principles were used to construct periods of uninterrupted
antibiotic therapy (therapy episodes) by linking related prescription records.
Rule definitions underpinning this linkage are available along with this
paper (Appendix S1, Table S2). This enabled identification of sequences of
drug administration making up therapy episodes, particularly transition
from one class of antimicrobials to another.
For each antimicrobial therapy episode, a dynamic table could be con-
structed with an hourly resolution capturing changes in therapy in relation
to clinical parameters (Table 3). It is used as the basis for analysing changes
of therapy in relation to clinical response to treatment (including tracking
the timing of conversion from IV to oral therapy administration).
Data processing software was written in Structured Query Language




Prescribing indication inference (supervised
classification)
PICS captures drug prescription indications as free text. Such information
was not made available to researchers as it contained patient identifiable
information. It was also affected by a high prevalence of missing data (in
the region of 50%). In order to demonstrate our approach, drug indications
were instead classified retrospectively using a training dataset that had
been collected during an audit of antibacterial prescribing conducted by
pharmacists between 2012 and 2017. This dataset included 4200 prescrip-
tions issued for 2712 patients in the following specialities: general medicine,
respiratory medicine, geriatric medicine and general surgery. Pharmacists
classified each prescription into 21 possible indications including ‘not speci-
fied’ and ‘other’ using data in PICS and paper medical records. A total of 463
prescriptions did not have a valid clinical indication, and 364 could not be
Table 1. Overview of antimicrobial stewardship metrics
Domain Measures
Antimicrobial consumption Proportion of hospital admissions with at least one antimicrobial prescription
Mean DOT (total duration of all prescriptions, including where there is overlap, e.g. combination therapy)
Mean LOT (time elapsed between the first and the last drug administration in an episode)
Rate of DOT and LOT per 1000 admissions29
Change of therapy (stop,
switch, continue)
Proportion of first-line monotherapy or combination therapy leading to a different choice of therapy, continu-
ation, or discontinuation
IV to oral administration switch Proportion of antimicrobial therapy episodes initiated by IV route being subsequently converted in full to oral
route
Mean time elapsed between IV therapy initiation and its complete conversion to oral therapy
Congruence with guidelines Proportion of antimicrobial therapy episodes initiated with one of the first-line treatment options listed in the
local empirical prescribing guidelines
Microbial culture taking Proportion of prescriptions belonging to a therapy episode initiated within 3 h of a blood, urine, skin or sterile site
microbial sample being taken
Table 2. ABCD criteria: considerations for IV to oral switch (see detailed criteria in Appendix S3)
Criteria Markers
A Afebrile for at least 24 h Temperature 36C–38C for 48 h
B Able to take oral medication (not measured) Functional gastrointestinal tract
No malabsorption
No interaction with other medications
Enteral drug form available
Patient can swallow and tolerate oral fluids via a tube
C Clinically improving No unexplained tachycardia (heart rate less than 90 beats/min in the
past 12 h)
Blood pressure stable in the past 24 h
Respiratory rate less than 20 breaths/min in the past 24 h
White cell count 4–12%109 cells/L OR a high white cell count that is falling
Falling C-reactive protein




Inadequately drained abscesses or empyema
Cavitating pneumonia
Staphylococcus aureus bacteraemia
Severe necrotizing soft tissue infections






Exacerbation of cystic fibrosis/bronchiectasis
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linked to electronic prescription records, restricting the analysis to a total of
3228 prescriptions corresponding to 2901 therapy episodes. Indication cat-
egories with fewer than 50 episodes (endocarditis, bronchiectasis, diabetic
foot and/or osteomyelitis, surgical prophylaxis) were reclassified as ‘other’.
These records were used as training data to predict the clinical indication
across all antimicrobial prescriptions, using random forest classification
with a moderate-to-low balanced accuracy of 59% overall. Predictive ana-
lytics were estimated using repeated 5-fold stratified cross-validation and
are reported in Appendix S2 and Table S4.
Results
Antimicrobial consumption descriptive characteristics
A basic characterization of prescribing requires linking prescriptions
into episodes of therapy, to describe their duration in relation to
patient demographics or type of infection treated. Between 1
September 2017 and 31 August 2018, there were 61 679 adult
admissions (46 853 distinct patients) across the six specialities.
Table 4 presents key metrics characterizing antibacterial use
(prevalence, duration, quantity) by age group. The mean length of
admission was 4.2 days, and 21 757 admissions (35%) contained
at least one antibacterial prescription. A total of 59884 antibacter-
ial prescriptions were issued, corresponding to 24511 antibacterial
therapy episodes, 141 of which spanned more than one admis-
sion. The mean length of antibacterial therapy episodes (LOT) was
5.8 days, equivalent to a mean 8.7 days of therapy (DOT) per ad-
mission. The mean DOT increased with age and was significantly
higher (9.9 days) in emergency admissions than in elective admis-
sions (4.3 days, Figure 1).
Changes of therapy
Changes of therapy could be analysed from the structure of ther-
apy episodes to identify escalation or de-escalation. For instance,
therapy episodes initiated with meropenem (n"969) were most
commonly: (i) stopped (33%) after a mean duration of 3.0 days; (ii)
continued (28%) after a mean duration of 2.0 days; (iii) switched to
piperacillin/tazobactam (12%) after a mean duration of 1.1 days;
or (iv) switched to co-amoxiclav (9.1%) after a mean duration of
1.9 days. Outcomes (i), (iii) and (iv) can be regarded as de-
escalation in this particular instance.
Switch from IV to oral therapy
Within 16688 out of the 24510 antibacterial therapy episodes, we
identified 17614 sequences consisting of one or more IV prescrip-
tions. Overall, 6404 (36%) of such the IV sequences were
converted into oral therapy, with a median and mean duration of
IV treatment of 2.4 days and 3.5 days, respectively. On the con-
trary, 11210 IV sequences (64%) continued with injections until
end of therapy, with a median duration of 1.3 days and a mean
duration of 3.5 days. As shown in Figure 2, variation in the conver-
sion to oral therapy across clinical teams and specialities was evi-
dent and can be attributed, at least in part, to case mix. For
instance, a likely explanation for cardiology’s lower conversion rate
(8%) is that prolonged IV therapy is recommended for deep-
seated infections such as endocarditis.
We sought to analyse the timeliness of conversion from IV to
oral therapy based on ABCD criteria (Table 2). Out of 6404 IV
sequences successfully switched, 2670 (42%) met A, C and D crite-
ria before oral conversion occurred. Out of 11210 sequences never
switched, 2682 (21%) met A, C and D criteria before end of therapy.
Across both sets, the delay between criteria being met and end/
conversion of therapy had a median of 2.1 days, a mean of
3.6 days [95% CI: 3.4–3.7], and a standard deviation of 5.7 days,
suggesting considerable variation. Figure 3 presents team- and
speciality-level mean delays, suggesting once again some differ-
ences between consultant teams within specialities.
Congruence with prescribing guidelines
We take the example of CAP. In addition to being the most com-
mon indication for therapy initiation, CAP prescribing guidelines
revolved around a widely adopted risk stratification score (CURB-
65) which could be measured from EHRs. Of 4222 therapy epi-
sodes initiated for CAP, 4109 (97%) could be linked with a CURB-65
severity score in the 48 h before or after antibiotic initiation
(assuming a mental confusion score of 0, as this information was
not recorded electronically). At the time of prescribing, QEHB
guidelines recommended:
• CURB-65 score 0 or 1: amoxicillin; doxycycline (penicillin
allergy).
• CURB-65 score 2: amoxicillin/clarithromycin; benzylpenicillin/
clarithromycin; moxifloxacin (penicillin allergy).
• CURB-65 score 3!: co-amoxiclav/clarithromycin; moxifloxacin
(penicillin allergy).
Table 5 reports antibiotics initiated as first-line therapy in 2569
low-severity CAP episodes, that is, episodes with a CURB-65 score
of 0 or 1. Out of 927 patients whose CURB-65 score can confidently
be assumed to be at the most 1 (score of 0 when omitting the
missing mental confusion score), just 207 (22%) therapy episodes
Table 3. Example structure of a therapy table




last 72 h Last CRP . . .
ABCD
criteria met?
X 2018-07-31 18:49:51 IV 11.0 #0.05 151 100 . . . yes
X 2018-07-31 19:49:51 IV 8.2 #0.02 151 100 . . . yes
X 2018-07-31 20:49:51 oral 8.2 #0.02 151 40 . . . yes
. . . . . . . . . . . . . . . . . . . . . . . . . . .
WBC, white blood cell count; CRP, C-reactive protein concentration.
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were initiated with the recommended drug, while 331 (36%)
received therapy recommended for higher CURB-65 scores,
demonstrating a preference for broad-spectrum antibiotics in
prescribers.
Microbial culture taking
Across a total of 59696 prescriptions ordered by six selected spe-
cialities, 22% (n"13210) were issued after at least one specimen
was sampled from blood, drains, respiratory tract, intravascular
devices, CNS, aspirates or other tissue or bone samples. Narrowing
the criterion to blood samples only, 18% (n"10906) of all pre-
scriptions and 38% (1174/3107) of prescriptions for meropenem
(mainly used to treat bloodstream infections), could be linked to
such a sample. Figure 4 reports findings broken down by speciality
and consultant team. Considerable variation can be observed,
which could be further examined in relation to variations in therapy




This single-site study demonstrates a pragmatic approach to com-
puting meaningful measures of AMS from electronic prescription,
laboratory and hospital care records to support stewardship teams
in rapidly identifying areas of prescribing behaviour where there is
scope for improved stewardship. In addition to measuring vari-
ation in antibiotic use, we demonstrate the feasibility of using rou-
tine data to assess overall compliance with guidelines (using the
example of CAP) and show how these datasets can be used to
compute a range of prescribing metrics (Table 1) built around inter-
national AMS recommendations. This can be used to monitor
performance; inform the design of stewardship interventions;
evaluate their impact; and engage clinical teams in audit and feed-
back interventions to optimize their prescribing.16
Study strengths and limitations
This study is novel in attempting to measure clinical constructs
that normally require manual audits or point prevalence surveys
using routinely collected data.28,37 We outlined ways of measuring
stewardship performance in clinical practice beyond antimicrobial
consumption, the main indicator currently used in stewardship
surveillance.38 National surveillance systems for prescribing and
resistance in secondary care provide high-quality measures of re-
sistance and prescribing for policy-makers, but they do not address
the needs of front-line clinicians who require more detailed metrics
to identify opportunities to improve their performance. This feasi-
bility study demonstrates the potential for locally developed
analytics to address the local needs and stewardship priorities of
clinicians using routinely collected EHRs. Future iterations of our
approach could be expanded to report on the effective and timely
use of surgical prophylaxis (and its congruence with guidelines),
timely initiation of antimicrobial therapy and adequate empirical
therapy coverage of microbial isolates.
Outside of intensive care research, existing literature contains
few examples of EHR research simultaneously analysing electronic
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large bespoke data engineering platforms have achieved this.39–41
Unlike the present study, such platforms exploit electronic mes-
sages streaming from hospital information systems in real-time:
these contain dynamic information, unlike the retrospective view
provided from EHRs commonly curated in hospital warehouses.
This noteworthy difference has implications: the structure and
content of electronic messages tend to be system-specific and re-






















































































Figure 3. Point and 95% CI estimates of the mean time (days) elapsed between ABCD criteria being met and conversion to oral therapy, ranked by
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Figure 2. Point and 95% CI estimates of the proportion of IV therapy converted into oral therapy ranked by consultant team by speciality
(September 2017–August 2018). The horizontal line indicates the point estimate for the entire speciality.
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analytical models. Such platforms are neither feasible in most hos-
pitals, nor justified for simple surveillance of antibiotic use, stew-
ardship performance and pathogen susceptibility. The
pragmatic approach described in the present paper would
be accessible to a wider range of hospitals, particularly if inter-
operable software35,36 and code lists/vocabularies are made
widely available. In those conditions, a modest proportion of
an information analyst’s time would be sufficient to validate
and map local data to standardized vocabularies and generate
comprehensive reports. Metrics specified in Table 1 are
designed to be feasible independently of variation in EHRs
and vocabularies across hospitals.
This feasibility study reveals the challenges associated with
assessing congruence with local prescribing guidelines and the
complexity of prescribing decisions. This is partly due to limitations
of routine data, but it also reflects a lack of consensus around
when and how to de-escalate antibiotics. Manual review of indi-
vidual prescribing records led authors to conclude that there is
too much ambiguity in EHRs to confidently assess the appropri-
ateness of individual prescribing decisions. Prescribing indica-
tion data were not available and made it necessary to rely upon
statistical classification. This introduced error into the findings:
for example, the classifier precision for CAP was 80% (Table S4),
indicating that one in five episodes classified as CAP were likely
to have a different indication. However, it is increasingly
common for prescribing indication to be recorded in electronic
prescribing systems which may make it feasible to assess con-
gruence with prescribing using EHRs alone. Similarly, the lack of
access to dispensing records prevented analysis of ‘to take
away’ medications issued at discharge, which can significantly
prolong the total LOT. Finally, prescription records were
obtained from a snapshot source and did not include a history
of changes made to prescriptions’ intended duration. This pre-
vented analysis of how frequently prescriptions were stopped
early. All analyses were restricted to structured data and did
not attempt to derive information that may have been recorded
in free text in medical notes.
Implications
Findings from this feasibility study are now informing the develop-
ment of an open-source software package35 designed to enable
hospitals to build their own stewardship analytics using routinely
collected EHRs. This has the potential to transform the delivery of
stewardship in hospitals by making detailed information on pre-
scribing patterns and resistance widely available in the context of
increasing use of electronic prescription, laboratory and hospital
care record systems in high-income nations. As of 2020, half of
England’s acute hospitals had adopted electronic prescribing.42
International guidelines2–7 recommend local investment into sur-
veillance and analytics to rationalize the use of antimicrobials. In
particular, the UK’s Antimicrobial Resistance National Action Plan16
aims to complete the introduction of electronic prescribing
systems across England by 2025, alongside the adoption of inter-
national clinical terminology in computerized laboratory sys-
tems.43 Strong evidence supports the use of feedback to
prescribers,2,44 but feedback needs to be relevant, targeted (team
or individual level), reliable and timely to influence prescribing be-
haviour.45 Further research is needed to statistically adjust those
measures for case mix in the same way as consumption meas-
ures.46 User-centred research47 is also needed to tailor these
measures to individual clinical teams, AMS teams and hospital
managers. There is also a need for research to develop evidence-
based standards of care for antimicrobial stewardship, for instance
to support decisions around de-escalation.48 This could be facili-
tated by observational studies of routine care records.
Conclusions
This study shows it is feasible to draw on electronic prescription, la-
boratory and hospital care records to provide meaningful meas-
ures of AMS, by:
(i) Reconstructing ‘therapy episodes’, which link all relevant
prescription records and enable analyses of the length,
changes and discontinuation of antimicrobial therapy.
(ii) Inferring the clinical intent and indication of prescriptions
(for both monotherapy and combination therapy). We have
illustrated the use of supervised classification in general
medicine specialities with moderate accuracy for the most
common infection categories.
(iii) Computing stewardship performance and quality metrics.
Examples include conversion of IV therapy to oral therapy
when patients show signs of resolution, microbial culture
sampling and congruence with guidelines.
Table 5. First-line therapy choice in CAP episodes in patients with a
CURB-65 score of 0 or 1
First-line therapy
Therapy episodes,
n (% column total)
URB-65"0 URB-65"1
Amoxicillin 205 (22.1) 249 (15.5)
Amoxicillin, clarithromycin 56 (6.0) 104 (6.5)
Azithromycin 4 (0.4) 6 (0.4)
Benzylpenicillin 2 (0.2) 3 (0.2)
Benzylpenicillin, clarithromycin 14 (1.5) 31 (1.9)
Benzylpenicillin, metronidazole 1 (0.1) 0 (0.0)
Ciprofloxacin 2 (0.2) 9 (0.6)
Clarithromycin 76 (8.2) 75 (4.7)
Clarithromycin, co-amoxiclav 261 (28.2) 541 (33.8)
Co-amoxiclav 104 (11.2) 211 (13.2)
Meropenem 9 (1.0) 24 (1.5)
Piperacillin/tazobactam 2 (0.2) 2 (0.1)
Ceftriaxone 10 (1.1) 2 (0.1)
Clarithromycin, moxifloxacin 2 (0.2) 4 (0.2)
Clarithromycin, piperacillin/
tazobactam
4 (0.4) 9 (0.6)
Meropenem, vancomycin 7 (0.8) 10 (0.6)
Other 168 (18.1) 322 (20.1)
Total 927 (100) 1602 (100)
URB-65, severity score based on CURB-65,25 with mental confusion item
set to 0: urea (blood urea nitrogen .7 mmol/L) (1 point), respirations
per min .30 (1 point), systolic blood pressure ,90 mmHg (1 point), age
65 years (1 point).
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However, one of the most significant obstacles hindering
hospitals’ stewardship efforts lies the difficulty in extracting and
analysing EHRs from a range of diverse systems.18 Reproducible
analytical tools are now available to assist microbiology culture
and susceptibility analytics.49 Software development is underway
to support other hospitals in adopting the approach tested in the
present study.35,36
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Figure 4. Point and 95% CI estimates of the proportion of prescriptions initiated with a blood culture sampled in the 3 days leading up to initiation of
prescription and/or therapy by consultant team by speciality by drug type in six selected specialities (September 2017–August 2018). Consultant
teams are ranked by percentage with a sample for ‘other’ antibiotic class. The horizontal line indicates the point estimate for the entire speciality.
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4 Haute Autorité de Santé. Antibiotic Therapy and Prevention of Bacterial
Resistance in Healthcare Organisations. Clinical Practice Guideline 2008.
https://www.has-sante.fr/jcms/c_665169/fr/strategie-d-antibiotherapie-
et-prevention-des-resistances-bacteriennes-en-etablissement-de-sante.
5 Pulcini C, Binda F, Lamkang AS et al. Developing core elements and check-
list items for global hospital antimicrobial stewardship programmes: a con-
sensus approach. Clin Microbiol Infect 2019; 25: 20–5.
6 Dellit TH, Owens RC, McGowan JE et al. Infectious Diseases Society of
America and the Society for Healthcare Epidemiology of America guidelines
for developing an institutional program to enhance antimicrobial steward-
ship. Clin Infect Dis 2007; 44: 159–77.
7 Stichting Werkgroep Antibiotica Beleid. A Teams Practical Guide.
Antimicrobial Stewardship in the Netherlands. https://swab.nl/en/download-
practice-guide.
8 Chung GWW, Wu JEE, Yeo CLL et al. Antimicrobial stewardship: a review of
prospective audit and feedback systems and an objective evaluation of out-
comes. Virulence 2013; 4: 151–7.
9 ECDC. Point Prevalence Survey of Healthcare-Associated Infections and
Antimicrobial Use in European Acute Care Hospitals – Protocol Version 5.3.
https://ecdc.europa.eu/en/publications-data/point-prevalence-survey-health
care-associated-infections-and-antimicrobial-use-3.
10 Howard P, Pulcini C, Levy HG et al. An international cross-sectional survey
of antimicrobial stewardship programmes in hospitals. J Antimicrob
Chemother 2014; 70: 1245–55.
11 Van Gastel E, Costers M, Peetermans WEE et al. Nationwide implementa-
tion of antibiotic management teams in Belgian hospitals: a self-reporting
survey. J Antimicrob Chemother 2010; 65: 576–80.
12 King A, Cresswell KM, Coleman JJ et al. Investigating the ways in which
health information technology can promote antimicrobial stewardship: a
conceptual overview. J R Soc Med 2017; 110: 320–9.
13 Hand KS, Cumming D, Hopkins S et al. Electronic prescribing
system design priorities for antimicrobial stewardship: a cross-sectional
survey of 142 UK infection specialists. J Antimicrob Chemother 2017; 72:
1206–16.
14 Cánovas-Segura B, Campos M, Morales A et al. Development of a clinical
decision support system for antibiotic management in a hospital environ-
ment. Prog Artif Intell 2016; 5: 181–97.
15 Curtis CE, Al Bahar F, Marriott JF. The effectiveness of computerised deci-
sion support on antibiotic use in hospitals: a systematic review. PLoS One
2017; 12: e0183062.
16 UK Department of Health and Social Care. Tackling Antimicrobial
Resistance 2019-2024. The UK’s Five-Year National Action Plan. https://www.
gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-re
sistance-2019-to-2024.
17 Baysari MT, Lehnbom EC, Li L et al. The effectiveness of information tech-
nology to improve antimicrobial prescribing in hospitals: a systematic review
and meta-analysis. Int J Med Inform 2016; 92: 15–34.
18 Micallef C, Chaudhry NT, Holmes AH et al. Secondary use of data from
hospital electronic prescribing and pharmacy systems to support the quality
and safety of antimicrobial use: a systematic review. J Antimicrob Chemother
2017; 72: 1880–5.
19 WHO. The ICD-10 Classification of Mental and Behavioural Disorders.
Clinical Descriptions and Diagnostic Guidelines. https://www.who.int/classifica
tions/icd/en/bluebook.pdf.
20 Health and Social Care Information Centre. OPCS Classification of





21 Nightingale PGG, Adu D, Richards NT et al. Implementation of rules based
computerised bedside prescribing and administration: intervention study.
BMJ 2000; 320: 750–3.
22 UK Health and Social Care Information Centre. dm!d Implementation
Guide (Secondary Care) V5.0. https://www.nhsbsa.nhs.uk/sites/default/files/
2017-02/Secondary_Care_Electronic_Prescribing_Implementation_
Guidance_5_0.pdf.
23 EUCAST. EUCAST Expert Rules Version 3.1. Intrinsic Resistance and
Exceptional Phenotypes Tables. http://www.eucast.org/fileadmin/src/
media/PDFs/EUCAST_files/Expert_Rules/Expert_rules_intrinsic_excep
tional_V3.1.pdf.
24 Magiorakos A-P, Srinivasan A, Carey RB et al. Multidrug-resistant,
extensively drug-resistant and pandrug-resistant bacteria: an international
expert proposal for interim standard definitions for acquired resistance. Clin
Microbiol Infect 2012; 18: 268–81.
25 Lim WS. Defining community acquired pneumonia severity on presenta-
tion to hospital: an international derivation and validation study. Thorax
2003; 58: 377–82.
26 EU-JAMRAI. Work Package 7. List of revised Guidelines; Tools and




27 PHE. Start Smart–Then Focus. Antimicrobial Stewardship Toolkit for
English Hospitals, https://www.gov.uk/government/publications/antimicro
bial-stewardship-start-smart-then-focus.
28 Seaton RA, Nathwani D, Burton P et al. Point prevalence survey of anti-
biotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool
(GAAT). Int J Antimicrob Agents 2007; 29: 693–9.
29 Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to im-
prove stewardship outcomes: methodology, opportunities, and challenges.
Infect Dis Clin North Am 2014; 28: 195–214.
Feasibility of hospital antimicrobial stewardship analytics JAR
9 of 10
30 Athanassa Z, Makris G, Dimopoulos G et al. Early switch to oral treatment
in patients with moderate to severe community-acquired pneumonia. Drugs
2008; 68: 2469–81.
31 UK Health and Social Care Information Centre. UK SNOMED CT Drug
Extension, RF2: Full, Snapshot & Delta. https://isd.digital.nhs.uk.
32 R Core Team. R: A Language and Environment for Statistical Computing.
https://www.r-project.org/.
33 Wickham H. tidyverse: Easily Install and Load the ‘Tidyverse’, https://
cran.r-project.org/package"tidyverse.
34 Wickham H, François R, Henry L et al. dplyr: A Grammar of Data
Manipulation, https://cran.r-project.org/package"dplyr.
35 Dutey-Magni PF, Shallcross L. Ramses: R Package for Antimicrobial
Stewardship & Surveillance [software]. https://github.com/ramses-antibiot
ics/ramses-package/. doi:10.5281/zenodo.4428900.
36 Dutey-Magni PF, Shallcross L. Ramses: R Package for Antimicrobial
Stewardship & Surveillance [software documentation]. https://ramses-antibi
otics.web.app/.
37 Charani E, de Barra E, Rawson TM et al. Antibiotic prescribing in general
medical and surgical specialties: a prospective cohort study. Antimicrob Resist
Infect Control 2019; 8: 151.
38 Vlahovic-Palcevski V, Gyssens IC et al. Quality indicators and quantity
metrics of antibiotic use. In: Pulcini C, Ergönül Ö, Can F, eds. Antimicrobial
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